P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation

Zhangsen Huang; Pu Liu; Linjing Zhu; Nailin Li; Hu Hu

doi:10.1160/TH13-09-0726

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(01): 142-150
DOI: 10.1160/TH13-09-0726

Platelets and Blood Cells

Schattauer GmbH

P2X₁-initiated p38 signalling enhances thromboxane A₂-induced platelet secretion and aggregation

Zhangsen Huang^*

¹Departmentof Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China

²Department of Medicine-Solna, Clinical Pharmacology Unit, Karolinska Institute, Stockholm, Sweden

,

Pu Liu^*

¹Departmentof Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China

,

Linjing Zhu

²Department of Medicine-Solna, Clinical Pharmacology Unit, Karolinska Institute, Stockholm, Sweden

,

Nailin Li

²Department of Medicine-Solna, Clinical Pharmacology Unit, Karolinska Institute, Stockholm, Sweden

,

Hu Hu

¹Departmentof Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China

› Author Affiliations

Abstract

Summary

ATP released by activated platelets can serve as a positive feedback machinery to amplify platelet responses by activating P2X₁ receptors. It has, however, not been defined how P2X₁ activities influence thromboxane A₂ (TXA₂)-stimulated platelet functional responses. Our aim was to elaborate the molecular mechanisms of P2X₁ engagements in TXA₂-induced platelet secretion and aggregation. P2X₁ inhibition by 1 µM NF449 inhibited platelet P-selectin expression induced by a low concentration of the TXA₂ analogue U46619 (0.3 µM) (32.0 ± 2.0% vs 43.4 ± 3.0%; n=5; p<0.05). p38 inhibition by SB203580, but not ERK inhibition by U0126, elicited a similar inhibition by NF499. The combination of NF449 and SB203580 provided, however, no additive effects. U46619-induced platelet aggregation was similarly decreased by NF449 and SB203580 alone or incombination, and by P2×1 pre-desensitisation with α,β-Me-ATP. U46619 caused rapid and reversible P2×1-dependent p38 phosphorylation. However, the P2X₁-p38 pathway mainly enhanced mild platelet activation by U46619, because α,β-Me-ATP supplementation or p38 blockade had no effect on intense platelet activation induced by a higher concentration of U46619 (3 µM). In conclusion, P2×1 activation, via p38 signalling, potentiates platelet activation initiated by low doses of U46619. Hence, the P2X₁-induced p38 signalling promotes more robust platelet activation in response to mild platelet stimuli.

Keywords

Platelets - ATP - P2X₁ - p38 - thromboxane A₂

Full Text

References

References
1 Brass LF, Manning DR, Cichowski K. et al. Signalling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 581-589.
2 Rao AK. Congenital disorders of platelet function: disorders of signal transduc-tion and secretion. Am J Med Sci 1998; 316: 69-76.
3 Dogne JM, Rolin S, de Leval X. et al. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 2001; 19: 87-96.
4 Hoylaerts MF, Oury C, Toth-Zsamboki E. et al. ADP receptors in platelet activation and aggregation. Platelets 2000; 11: 307-309.
5 Sun B, Li J, Okahara K. et al. P2X1 purinoceptor in human platelets Molecular cloning and functional characterisation after heterologous expression. J Biol Chem 1998; 273: 11544-11547.
6 Wang L, Ostberg O, Wihlborg AK. et al. Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 2003; 01: 330-336.
7 MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2×1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-2881.
8 Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2×1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001; 85: 303-308.
9 Erhardt JA, Pillarisetti K, Toomey JR. Potentiation of platelet activation through the stimulation of P2×1 receptors. J Thromb Haemost 2003; 01: 2626-2635.
10 Hechler B, Lenain N, Marchese P. et al. A role of the fast ATP-gated P2×1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198: 661-667.
11 Oury C, Kuijpers MJ, Toth-Zsamboki E. et al. Overexpression of the platelet P2×1 ion channel in transgenic mice generates a novel prothrombotic pheno-type. Blood 2003; 101: 3969-3976.
12 Toth-Zsamboki E, Oury C, Cornelissen H. et al. P2×1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem 2003; 278: 46661-46667.
13 Fung CY, Brearley CA, Farndale RW. et al. A major role for P2×1 receptors in the early collagen-evoked intracellular Ca2+ responses of human platelets. Thromb Haemost 2005; 94: 37-40.
14 Fung CY, Cendana C, Farndale RW. et al. Primary and secondary agonists can use P2X(1) receptors as a major pathway to increase intracellular Ca(2+) in the human platelet. J Thromb Haemost 2007; 05: 910-917.
15 Fung CY, Jones S, Ntrakwah A. et al. Platelet Ca(2+) responses coupled to glyco-protein VI and Toll-like receptors persist in the presence of endothelial-derived inhibitors: roles for secondary activation of P2×1 receptors and release from in-tracellular Ca(2+) stores. Blood 2012; 119: 3613-3621.
16 Hechler B, Magnenat S, Zighetti ML. et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4’,4’’,4’’’-(carbonylbis(imino-5,1,3-ben-zenetriylbis-(carbonylimino)))tetrakis -benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Therapeut 2005; 314: 232-243.
17 Erhardt JA, Toomey JR, Douglas SA. et al. P2×1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 2006; 04: 882-890.
18 Oury C, Daenens K, Hu H. et al. ERK2 activation in arteriolar, venular murine thrombosis: platelet receptor GPIb vs P2X. J Thromb Haemost 2006; 04: 443-452.
19 Oury C, Toth-Zsamboki E, Vermylen J. et al. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002; 100: 2499-2505.
20 Saklatvala J, Rawlinson L, Waller RJ. et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 1996; 271: 6586-6589.
21 Siljander P, Farndale RW, Feijge MA. et al. Platelet adhesion enhances the glyco-protein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001; 21: 618-627.
22 Woehrle T, Yip L, Manohar M. et al. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptors. J Leuk Biol 2010; 88: 1181-1189.
23 Hu H, Li N, Yngen M. et al. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 02: 58-64.
24 Minuz P, Gaino S, Zuliani V. et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 2002; 87: 888-898.
25 Dangelmaier C, Jin J, Daniel JL. et al. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem 2000; 267: 2283-2289.